Merck & Co., Inc. (MRK)
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's stock is undervalued, trading at less than 4x expected 2024 revenues, despite strong revenue growth from Keytruda and other drugs. Keytruda's revenue is projected to increase by 70% from 2024 to 2032. Declining Gardasil sales in China and competition from Summit Therapeutics and Roche's Tecentriq may have contributed to recent stock volatility.
Merck signs $3.3 bln deal for experimental cancer drug
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) UBS Global Healthcare Conference November 13, 2024 12:30 PM ET Company Participants Jannie Oosthuizen - President of Human Health of the U.S. Joerg Koglin - SVP of Clinical Research Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think we're at time here.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
If you're patient, these businesses have a lot of promising projects in the works.
Merck: An Undervalued Dividend Machine
Keytruda, Merck's flagship oncology drug, drives significant revenue growth, with a solid market position and patent protection ensuring continued growth. Merck is the second largest player in the oncology drugs industry, which is expected to observe a 6.7% CAGR over the next five years. Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment appeal.
Is MRK Stock Undervalued At $100?
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compared to the consensus estimates of $16.5 billion and $1.50, respectively.
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
These stocks near 52-week lows could be ready to rebound.
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
On Thursday, Merck & Co Inc MRK reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion.
Is Merck Stock a Buy?
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
Merck & Co., Inc. (MRK) Q3 2024 Earnings Conference Call Transcript
Start Time: 09:00 January 1, 0000 10:00 AM ET Merck & Co., Inc. (NYSE:MRK ) Q3 2024 Earnings Call October 31, 2024, 09:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li - President of Merck Research Labs Conference Call Participants Chris Shibutani - Goldman Sachs Daina Graybosch - Leerink Partners Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Trung Huynh - UBS Louise Chen - Cantor Carter Gould - Barclays Umer Raffat - Evercore ISI Steve Scala - TD Cowen Mohit Bansal - Wells Fargo Operator Thank you for standing by. Welcome to the Merck & Company Q3 Sales and Earnings Conference Call.
